Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Progression‐free survival · people with cutaneous melanoma

BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.56 [0.44, 0.71]
1784 participants
Moderate